Arkolith/Insider Trading/VINC/Form 4

Izumi Raquel E.

See Remarks, DirectorVincerx Pharma, Inc. (VINC) · full profile →Form 4 · filed Aug 10, 2023
Net Buying
Open-Market Buys
$15K
Open-Market Sells
$0
Net Open-Market Flow
$15K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 10, 2023Buy(P)3K$0.93$3K85K
Aug 9, 2023Buy(P)13K$0.90$12K82K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-041513) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML